Cortical excitability in smoking and not smoking individuals with and without nicotine.

What Was Tested

Researchers studied Therapeutic nicotine (patch, non-peptide) in this randomized controlled trial publication.

The researchers therefore aimed to explore the effect of nicotine intake on cortical excitability in healthy human smokers and non-smokers.

Why It Was Studied

Activation of nicotinic acetylcholine receptors has a major neuromodulatory impact on central nervous system function.

Beyond acute activation, chronic nicotine intake has long-lasting effects on cortical excitability in animal experiments, caused by receptor up- or down-regulation.

Who Took Part

PubMed indexes the participants as young adults and adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized study.

The participants were allocated by chance, so the Therapeutic nicotine (patch, non-peptide) group and the comparison group should start out alike.

The primary motor cortex served as model, and cortical excitability was monitored via transcranial magnetic stimulation (TMS).

Corticospinal excitability and intracortical excitability were recorded before and after application of nicotine patch in both groups.

Corticospinal excitability was explored by motor threshold and input/output curve (I/O curve), and intracortical excitability was explored by means of paired-pulse TMS techniques (intracortical facilitation (ICF), short-latency intracortical inhibition (SICI), I-wave facilitation and short-latency afferent inhibition (SAI)).

What Was Measured

The subject headings attached to it are Evoked Potentials, Motor, Motor Cortex, Nicotine, Nicotinic Agonists, Smoking, Transcranial Magnetic Stimulation and Transdermal Patch.

What This Means in Plain Language

The paper is a randomized study of Therapeutic nicotine (patch, non-peptide).

The abstract goes on to report its results in about 3 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2013 (Psychopharmacology), a journal based in Germany.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.